Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria

An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy

Kasper Broedbaek, MD1,2
Trine Henriksen, PhD1,2
Allan Weimann, PhD1,2
Morten Petersen, MD1,2
Jon T. Andersen, MD1,2
Shoaib Afzal, MD1,2
Espen Jimenez-Solem, MD1,2
Frederik Persson, MD3
Hans-Henrik Parving, DMSc4,5,6
Peter Rossing, DMSc3
Henrik E. Poulsen, DMSc1,2,6

OBJECTIVE—We tested whether long-term treatment with the angiotensin II receptor antagonist irbesartan reduces nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria.

RESEARCH DESIGN AND METHODS—The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study was a 2-year multicenter randomized double-blind trial comparing irbesartan (150 and 300 mg once daily) with placebo. We studied a subgroup of 50 patients where urine samples were available for analysis of albumin and the oxidatively modified guanine nucleosides 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanosine (8-oxoGuo).

RESULTS—During the 2-year trial, no significant differences in 8-oxodG and 8-oxoGuo excretion between placebo and irbesartan treatment were seen. 8-oxodG and albumin excretion decreased with time (P = 0.004 and P < 0.0001, respectively), whereas treatment-related differences were shown for albumin excretion (P = 0.0008) only, as previously reported. Important secondary findings were significant associations between changes in 8-oxodG excretion and changes in albumin excretion and glycated hemoglobin (HbA1c). During the study period, 8-oxodG excretion decreased by 3 and 26% in smokers and nonsmokers, respectively (P = 0.013), and urinary albumin excretion decreased 22% in smokers and 58% in nonsmokers (P = 0.011).

CONCLUSIONS—Irbesartan treatment was not significantly more effective than placebo in reducing nucleic acid oxidation. The results indicate that DNA oxidation in diabetes patients is reduced by various components in the treatment of diabetes where glycemic control seems to be important and addition of angiotensin II receptor antagonists does not lead to any substantial additional reduction. Furthermore, the reductions in DNA oxidation and albumin excretion seem to be counteracted by smoking.
whether smoking status had any in hoc analyses were carried out to examine and microalbuminuria. In addition, post hoc.

Because other studies have shown differences in the rate of oxidative DNA damage between smokers and nonsmokers (8,9) and associations between smoking and progression of diabetic nephropathy (10–12), we chose to assess the effect of smoking post hoc.

The primary aim of this study was to determine whether long-term treatment with the angiotensin II receptor antagonist irbesartan reduces DNA and RNA oxidation in patients with type 2 diabetes and microalbuminuria. In addition, post hoc analyses were carried out to examine whether smoking status had any influence on changes in nucleic acid oxidation and albumin excretion during the trial.

RESEARCH DESIGN AND METHODS—The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study protocol has been described in detail elsewhere (7). In brief, 590 hypertensive type 2 diabetic patients with microalbuminuria were included in this multinational randomized double-blind placebo-controlled study of irbesartan (150 and 300 mg) and were followed for 24 months. The primary outcome was time to onset of diabetic nephropathy, defined as persistent albuminuria in overnight specimens with a urinary albumin excretion rate >200 μg/min and ≥30% increase from baseline level. Target trough blood pressure was <135/85 mmHg 3 months after randomization. Additional antihypertensive treatment used included diuretics, calcium-channel blockers (except dihydropyridines), and β-blockers. These agents were added if target blood pressure was not reached 3 months after randomization. The study was approved by the regional ethics committees and conducted in accordance with the Helsinki Declaration.

Data ascertained for this study were collected from a subgroup of 50 Danish patients from the original IRMA 2 study who were followed at the outpatient clinic at the Steno Diabetes Center. Measurements of blood pressure, weight, glomerular filtration rate (GFR), serum hemoglobin concentration, glycated hemoglobin (HbA1c), concentration, urinary albumin excretion, urinary 8-oxoG and 8-oxoGuo, and other laboratory evaluations were performed at baseline and at 3, 12, and 24 months.

Blood pressure was measured with a sphygmomanometer in the sitting position after at least 10 min of rest. HbA1c was determined by ion-exchange high-performance liquid chromatography. The hemoglobin, cholesterol, and triglyceride concentrations were analyzed with standard laboratory assays. GFR was measured after a single intravenous injection of 5 MBq 51Cr-EDTA at 8:00 a.m. by determining the radioactivity in venous blood samples taken 180, 200, 220, and 240 min after the injection, considering sex and body weight of the patient. The results were standardized for 1.73 m² body surface area.

The urinary albumin concentration was determined by nephelometry and the creatinine concentration in serum and urine by the Jaffe reaction.

Spot urine samples, stored at −80°C until analysis, were assayed in 2009 for the oxidatively modified guanine nucleosides 8-oxoG and 8-oxoGuo using ultra-performance liquid chromatography and tandem mass spectrometry. 8-oxoG and 8-oxoGuo were normalized against urinary creatinine concentration. Chromatographic separation was performed on an Acuity UPLC system (Waters, Milford, MA). The column used was an Acuity BEH Shield RP18 column (1.7 μm, 2.1 × 100 mm) protected with an in-line filter (4 × 2 mm, 0.2 μm), both obtained from Waters.

The mass spectrometric detection was performed on an API 3000 triple quadrupole mass spectrometer (Sciex, Toronto, Canada) equipped with an electrospray ion source (Turbospray) operated in the positive mode. Details of the analysis are described elsewhere (13).

Statistical analysis
Baseline characteristics were compared using the χ² test for categorical variables and ANOVA for continuous variables. Results are presented as mean ± SD for normally distributed variables or median (interquartile range) for nonnormally distributed variables. Pair-wise comparisons were performed using the paired or unpaired Student t test or Mann-Whitney test.

Repeated-measures ANOVA models were used to analyze the effect of intervention on nucleic acid oxidation and urinary albumin excretion. Repeated-measures ANOVA models were also used to analyze the effect of smoking, where comparison of changes in urinary 8-oxoG, 8-oxoGuo, and albumin excretion and other possible confounding factors (weight, blood pressure, HbA1c, GFR, and hemoglobin) between smokers and nonsmokers were made. Interaction terms were added to the models to assess interaction between smoking, time, and irbesartan treatment (time × smoking × treatment group effect).

Linear regression models were used to assess the relationship between changes in urinary 8-oxoG/8-oxoGuo and changes in diabetes-related variables and possible confounders of oxidative stress (albumin excretion, weight, blood pressure, HbA1c, GFR, and hemoglobin). Interactions between treatment group and changes in albumin excretion, weight, blood pressure, HbA1c, GFR, and hemoglobin were assessed by adding interaction terms to the models. Linear regression analysis was used to determine the relationship between baseline variables and changes in urinary 8-oxoG and 8-oxoGuo as well. Because of deviation from normal distribution, the variables 8-oxoG, 8-oxoGuo, and albumin albumin excretion were log-transformed before calculation.

All statistical analyses were performed using the SAS software version 9.1 (SAS Institute, Cary, NC). Statistical significance was defined as P < 0.05. All statistical tests were two-sided.

RESULTS—Treatment groups were balanced with respect to baseline demographic, clinical, and biochemical characteristics (Table 1). There were no statistically significant differences in the use of additional hypertensive and cholesterol-lowering treatment between the groups (Supplementary Table 1).

Effects of irbesartan treatment
Changes in 8-oxoG, 8-oxoGuo, and albumin excretion according to treatment group during the study are shown in Fig. 1. No significant differences in 8-oxoG
and 8-oxoGuo excretions between placebo and irbesartan treatment were seen during the trial. Urinary 8-oxoG excretion decreased by 23% (P = 0.06), 12% (P = 0.1), and 18% (P = 0.01) in the placebo, 150 mg irbesartan, and 300 mg irbesartan groups, respectively.

Analysis by repeated-measures ANOVA showed that 8-oxoG excretion decreased with time (time effect, P = 0.0004), whereas no significant treatment × time interaction was seen (treatment × time effect, P = 0.46), reflecting no treatment-related differences in the rate of change over time (Fig. 1A). No effect of time or treatment on 8-oxoGuo excretion was shown (Fig. 1B).

Albunin excretion decreased during the study period (time effect, P < 0.0001) and a significant treatment × time interaction was shown for urinary albumin excretion (treatment × time effect, P = 0.0008), reflecting treatment-related differences in the rate of change during the trial, where the albumin excretion decreased by 16, 33, and 71% in the placebo, 150 mg irbesartan, and 300 mg irbesartan groups, respectively (Fig. 1C).

**Post hoc analyses**

**Associations between nucleic acid oxidation and other variables.** Simple regression analysis was used to evaluate the relationship between changes in nucleic acid oxidation and changes in urinary albumin excretion, weight, blood pressure, HbA1c, GFR, and hemoglobin (Supplementary Table 2).

The combined data of all the subjects showed significant positive association (R² = 0.18, P = 0.014) between percentage changes in 8-oxoG excretion and urinary albumin excretion, significant positive association (R² = 0.18, P = 0.015) between the percentage changes in 8-oxoG excretion and HbA1c, and significant negative association (R² = 0.13, P = 0.04) between percentage changes in 8-oxoG excretion and weight over the 2-year study period. There were no significant associations between changes in 8-oxoGuo and changes in urinary albumin excretion, weight, blood pressure, HbA1c, GFR, and hemoglobin.

Possible effect modification by the variables urinary albumin excretion, weight, blood pressure, HbA1c, GFR, and hemoglobin were assessed in the interaction analyses. For changes in 8-oxoG and 8-oxoGuo excretion, no interactions between treatment group and changes in the above-mentioned variables were found (data not shown).

Significant associations between percentage changes in 8-oxoG excretion and the baseline values of 8-oxoG, HDL cholesterol, and age were found. Greater 8-oxoG excretion (R² = 0.26, P = 0.002), HDL cholesterol (R² = 0.31, P = 0.0008), and age (R² = 0.14, P = 0.03) at baseline were related to greater reduction in 8-oxoG excretion during the trial (Supplementary Table 2).

**Effects of smoking.** Effects of time and smoking on urinary 8-oxoG, 8-oxoGuo, and albumin excretions are shown in Fig. 2. At baseline, there were no significant differences in albumin (P = 0.35), 8-oxoG (P = 0.10), and 8-oxoGuo (P = 0.41) excretions between smokers and nonsmokers.

Regardless of treatment regimen, both the excretion of 8-oxoG and urinary albumin showed significant group × time interactions, reflecting differences in the rate of change during the trial between smokers and nonsmokers. During the 2-year study period, 8-oxoG excretion decreased by 3% in smokers and 26% in nonsmokers (smoking group × time effect, P = 0.015) (Fig. 2A). Urinary albumin excretion decreased 22% in smokers and 58% in nonsmokers (smoking group × time effect, P = 0.011) (Fig. 2C).

No significant difference in change in urinary 8-oxoGuo between smokers and nonsmokers was shown. Figure 2B gives an impression of a difference between smokers and nonsmokers, where smokers had an increase and nonsmokers a decrease in 8-oxoGuo excretion during the trial, but a significant difference could not be shown, even when including only baseline and 2-year measurements in the analysis (smoking group × time effect, P = 0.10; baseline + 2-year smoking group × time effect, P = 0.08).

No interaction between smoking, time, and irbesartan treatment (time × smoking × treatment group effect) was shown for albumin, 8-oxoGuo, and 8-oxoG excretions (data not shown). When treatment interaction was included in the analysis, the differences between smokers and nonsmokers were still significant for both 8-oxoG (smoking group × time effect, P = 0.03) and albumin excretion (smoking group × time effect, P = 0.02).

There were no significant differences in any of the baseline variables between smokers and nonsmokers, and changes in weight, blood pressure, HbA1c, GFR, and hemoglobin during the trial did not differ between the two groups (data not shown).

**CONCLUSIONS—**Our study demonstrates a reduction of the urinary excretion of 8-oxoG during the 2-year trial period in 50 type 2 diabetic patients with microalbuminuria. However, there was no significant effect of treatment with
irbesartan on 8-oxodG excretion compared with placebo treatment.

In previous studies, significant reductions in 8-oxodG excretion were shown after short-term treatment with candesartan for 12 weeks in 64 patients with essential hypertension (5) and with candesartan/valsartan for 8 weeks in 33 type 2 diabetic patients with nephropathy (3). Miyashita et al. (6) demonstrated a significant reduction of urinary excretion of 8-oxodG after 12 months of olmesartan treatment in 35 type 2 diabetic patients with hypertension.

Ogawa et al. (3), Dohi et al. (5), and Miyashita et al. (6) did not find significant reductions in 8-oxodG excretion in the comparison groups (calcium-channel blocker group, control group, and thiaclothromethiazide group), but none of the studies included comparison with a placebo group, and tests of significance of the differences between the groups were only performed in one study.

We assessed confounders by identifying associations between 8-oxodG and 8-oxoGuo excretions and other measured variables, and by performing analysis of interactions between treatment group and changes in the variables urinary albumin excretion, weight, blood pressure, HbA1c, GFR, and hemoglobin. No important confounders were identified in these analyses.

The fact that 8-oxodG excretion was reduced in a similar degree in irbesartan and placebo treatment indicates that the shown reduction in DNA oxidation is most likely induced by other factors in the pharmacological or nonpharmacological treatment of diabetes. We found a significant association between change in 8-oxodG excretion and change in HbA1c, which suggests that glycemic control is important regarding the reduction in DNA oxidation. Reduction in HbA1c was associated with a reduction in 8-oxodG excretion rate, reflecting diminished DNA oxidation, and this association was shown in other studies (14–17). To explain the association between hyperglycemia and DNA oxidation, several mechanisms have been suggested. One possible mechanism is hyperglycemia-induced mitochondrial reactive oxygen species production, which in turn leads to induction of DNA damage (18,19).

As previously shown in the original IRMA 2 study (7) and in the Microalbuminuria Reduction With Valsartan (MARVAL) study (20), treatment-related differences in the rate of change in urinary albumin excretion during the trial was demonstrated in this study, where irbesartan treatment led to a greater reduction in albumin excretion than placebo.

The reduction of albumin excretion rate was shown to be associated with a reduction in 8-oxodG excretion in this
study, and this positive association was also shown by Ogawa et al. (3).

This relationship between albumin and 8-oxodG excretion is indeed noteworthy considering that albumin excretion is currently the best available noninvasive means of following the course of kidney disease in nonproteinuric diabetic patients (21) and is an independent predictor of increased risk for cardiovascular morbidity and mortality in patients with diabetes and hypertension, as well as in the general population (22).

Whether albumin excretion and excretion of 8-oxodG express the same, different, or overlapping pathophysiological mechanisms in diabetes is unknown. As albumin excretion is considered to primarily reflect renal damage and 8-oxodG excretion expresses the whole-body DNA oxidation, it seems likely that 8-oxodG excretion contains additional pathophysiological information. This leaves open the possibility that 8-oxodG excretion could be used as a supplement to albumin excretion in diabetes care. The main question in this context is whether patients experiencing both reductions in 8-oxodG and albumin excretion have a better prognosis than patients with reduction in albumin excretion but with no reduction in 8-oxodG excretion. This question must be addressed on a larger scale, which underlines the relevance of large-scale studies evaluating the predictive role of changes in 8-oxodG excretion for morbidity and mortality in diabetes.

Elevated 8-oxodG excretion, HDL cholesterol, and age at baseline were associated with greater reduction in 8-oxodG excretion during the trial. HDL cholesterol has been shown to be a predictor of progression to overt nephropathy, independently of the presence of microalbuminuria or hypertension, where higher levels of HDL cholesterol are associated with a lower risk of nephropathy (23). That high levels of HDL cholesterol are associated with greater reductions in 8-oxodG leaves open the possibility that DNA oxidation could play a role in the reduced risk of nephropathy at higher HDL cholesterol levels. This association should be investigated further for confirmation.

A significant difference in the change in 8-oxodG excretion and urinary albumin excretion between smokers and nonsmokers was seen. Nonsmokers had a greater reduction in both 8-oxodG excretion and albumin excretion during the trial period.

These results are in accordance with earlier studies of the relationship between smoking and development of nephropathy in type 2 diabetes, where smoking promotes the onset and progression of nephropathy (10–12). Smoking has also been shown to exacerbate
markers of kidney failure, such as microalbuminuria (24,25), and smoking cessation has been shown to reduce the progressive damage to the kidneys in type 2 diabetes (11).

Our results indicate that smoking status is not only a predictor of nephropathy but also an important predictor of the change in DNA oxidation in type 2 diabetic patients with microalbuminuria.

The statistical power of our analysis is limited by the relatively small sample size. However, the size of our population is sufficient to show significant reductions in 8-oxoG and albumin excretion and to show the significant difference in albumin excretion between placebo and irbesartan treatment. Given the three-group design, our study had 93% power to detect an effect size of 0.56 in the change in albumin excretion, which is considered to be a large effect. The effect size of the change in 8-oxoG excretion was in our study estimated to be only 0.14, and with such a small effect size, it would require a total sample size of 450 to achieve 80% power. This means that if a difference in the change in 8-oxoG excretion between the groups actually exists, it is too small to be detected here, since our study was not designed to detect such small differences.

Another important limitation of our study is that no information regarding changes in smoking patterns was available. We cannot rule out that changes in smoking habits during the trial could be a confounder regarding treatment effects. In this study, we conclude that patients who were smokers at baseline had a smaller reduction in albumin and 8-oxoG excretion than nonsmokers, but the effect of smoking reduction/cessation could not be investigated.

Despite the limitations described above, strengths that distinguish the current evaluation from previous studies are that our study has the benefit of being a placebo-controlled trial and having a longer observation period than previous studies of the relationship between renin-angiotensin-aldosterone system inhibition and DNA oxidation.

In summary, in patients with type 2 diabetes and microalbuminuria, long-term treatment with the angiotensin II receptor antagonist irbesartan did not lead to a greater reduction in urinary excretion of nucleic acid oxidation markers than placebo treatment. Post hoc analyses showed significant associations between changes in 8-oxoG excretion and changes in albumin excretion and HbA1c, and a greater reduction in both the urinary excretion of the DNA oxidation marker 8-oxoG and albumin in non-smokers than in smokers.

These results indicate that DNA oxidation in diabetic patients is reduced by various factors in the diabetes treatment, where glycemic control seems to be important, and addition of angiotensin II receptor blockers does not have a significant effect on nucleic acid oxidation. Furthermore, the reductions in DNA oxidation and albumin excretion seem to be counteracted by smoking.

Acknowledgments—This study was supported by research funding from the Research Committee at Copenhagen University Hospital—Rigshospitalet (Rigshospitalets Forskningsudvalg), the Danish Medical Research Council, Aase and Ejnar Danielsen Foundation, and P. Carl Petersen Foundation.

No potential conflicts of interest relevant to this article were reported.

K.B. researched data, contributed to discussion, reviewed and edited the manuscript, and wrote the manuscript. T.H. and A.W. researched data and reviewed and edited the manuscript. M.P., J.T.A., S.A., and E.J.-S. researched data, contributed to discussion, and reviewed and edited the manuscript. F.P., H.-H.P., and P.R. researched data and reviewed and edited the manuscript. H.E.P. researched data, contributed to discussion, and reviewed and edited the manuscript.

References

Irbesartan, smoking, and nucleic acid oxidation


